Histone H3 (di methyl Lys4) Antibody (Rabbit mAb) [G7H21]

Application: Reactivity: Mouse, Rat, Chicken, Cow, Human, African green monkey

Usage Information

Dilution
WB1:2000 IP1:30 IHC1:800 IF1:1000 FCM1:20 - 1:100 CHIP1:500

Application
WB, IP, IHC, IF, FCM, ChIP

Reactivity
Mouse, Rat, Chicken, Cow, Human, African green monkey

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
15 kDa 17 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
Histone H3 (di methyl Lys4) Antibody (Rabbit mAb) [G7H21] detects endogenous levels of total Histone H3 protein only when it is dimethylated at Lys4.

Clone
G7H21

Synonym(s)
H3FA, HIST1H3A, H3C2, H3FL, HIST1H3B, H3C3, H3C7, H3FI, HIST1H3F, H3C8, H3FH, HIST1H3G, H3C10, H3FK, HIST1H3J, H3C1, H3FC, Histone H3/l, H3K4me2, H3K4me, H3K4

Background
Histone H3 (dimethyl Lys4), commonly termed H3K4me2, is a post-translational modification on the N‑terminal tail of core histone H3 that occupies an intermediate state in the H3K4 methylation hierarchy and functions as a chromatin signal linked to active and poised transcription, enhancer activity and tissue-specific regulatory programs. The mark lies on lysine 4 within the flexible histone tail that protrudes from the nucleosome surface, and exists alongside mono- and tri‑methylated forms that together shape distinct chromatin environments; H3K4me2 is deposited primarily by SET1/COMPASS family methyltransferase complexes and removed by demethylases such as LSD1 and JARID1/KDM5 family enzymes, establishing a dynamic methylation–demethylation cycle that responds to developmental and signaling cues. Genome-wide mapping shows that H3K4me2 is enriched over promoters and 5′ transcribed regions of active genes, extending further into gene bodies than H3K4me3, and also marks a large set of enhancers and transcription factor binding regions, where it co-occurs with H3K27ac to delineate robust enhancer–promoter interactions and helps define chromatin loops that connect distal regulatory elements to target genes. Mechanistically, H3K4me2 serves as a docking site for reader proteins containing PHD fingers and other methyl-lysine binding domains, and in mammals it recruits the Set3 HDAC complex to 5′ coding regions, where Set3 deacetylates histones and modulates transcription elongation and nucleosomal turnover, thereby tuning gene expression levels rather than simply switching genes on or off. In enhancer contexts, H3K4me2 distinguishes a class of regulatory elements that are engaged by pluripotency factors and other lineage-determining transcription factors during early development: in vertebrate embryos H3K4me2 marks enhancers bound by Nanog, OCT4/Pou5f3 and Sox19b, and these enhancers become central to maternal-to-zygotic genome activation and the establishment of cell fate–specific transcriptional programs. Tissue-specific profiling reveals that H3K4me2 landscapes differ across organs, with distinct patterns in neural and muscle tissue reflecting its role in controlling genes for neuronal differentiation, synaptic plasticity and myogenesis, and alterations in these patterns in degenerative muscle disease and neurodevelopmental disorders point to mis-regulation of H3K4me2-dependent enhancers and promoter–enhancer communication. In cancer, H3K4 modifications, including H3K4me2, are frequently perturbed through mutations or misexpression of COMPASS methyltransferases and LSD1/KDM5 demethylases; these changes affect chromatin accessibility, transcription factor occupancy and gene expression dynamics in pathways controlling proliferation, apoptosis and differentiation, and H3K4me2 profiles at promoters and enhancers are being explored as biomarkers and as readouts of response to epigenetic therapies targeting H3K4-modifying enzymes. Di‑methylation of histone H3 Lys4 represents a structural feature of nucleosomes that encodes regulatory information about transcriptional activity and potential, integrates with acetylation and other histone marks to organize promoter and enhancer chromatin, and provides a mechanistic handle for researchers investigating gene regulation, developmental transitions, epigenetic dysregulation in disease and related immune pathologies.

Background

Histone H3 (dimethyl Lys4), commonly termed H3K4me2, is a post-translational modification on the N‑terminal tail of core histone H3 that occupies an intermediate state in the H3K4 methylation hierarchy and functions as a chromatin signal linked to active and poised transcription, enhancer activity and tissue-specific regulatory programs. The mark lies on lysine 4 within the flexible histone tail that protrudes from the nucleosome surface, and exists alongside mono- and tri‑methylated forms that together shape distinct chromatin environments; H3K4me2 is deposited primarily by SET1/COMPASS family methyltransferase complexes and removed by demethylases such as LSD1 and JARID1/KDM5 family enzymes, establishing a dynamic methylation–demethylation cycle that responds to developmental and signaling cues. Genome-wide mapping shows that H3K4me2 is enriched over promoters and 5′ transcribed regions of active genes, extending further into gene bodies than H3K4me3, and also marks a large set of enhancers and transcription factor binding regions, where it co-occurs with H3K27ac to delineate robust enhancer–promoter interactions and helps define chromatin loops that connect distal regulatory elements to target genes. Mechanistically, H3K4me2 serves as a docking site for reader proteins containing PHD fingers and other methyl-lysine binding domains, and in mammals it recruits the Set3 HDAC complex to 5′ coding regions, where Set3 deacetylates histones and modulates transcription elongation and nucleosomal turnover, thereby tuning gene expression levels rather than simply switching genes on or off. In enhancer contexts, H3K4me2 distinguishes a class of regulatory elements that are engaged by pluripotency factors and other lineage-determining transcription factors during early development: in vertebrate embryos H3K4me2 marks enhancers bound by Nanog, OCT4/Pou5f3 and Sox19b, and these enhancers become central to maternal-to-zygotic genome activation and the establishment of cell fate–specific transcriptional programs. Tissue-specific profiling reveals that H3K4me2 landscapes differ across organs, with distinct patterns in neural and muscle tissue reflecting its role in controlling genes for neuronal differentiation, synaptic plasticity and myogenesis, and alterations in these patterns in degenerative muscle disease and neurodevelopmental disorders point to mis-regulation of H3K4me2-dependent enhancers and promoter–enhancer communication. In cancer, H3K4 modifications, including H3K4me2, are frequently perturbed through mutations or misexpression of COMPASS methyltransferases and LSD1/KDM5 demethylases; these changes affect chromatin accessibility, transcription factor occupancy and gene expression dynamics in pathways controlling proliferation, apoptosis and differentiation, and H3K4me2 profiles at promoters and enhancers are being explored as biomarkers and as readouts of response to epigenetic therapies targeting H3K4-modifying enzymes. Di‑methylation of histone H3 Lys4 represents a structural feature of nucleosomes that encodes regulatory information about transcriptional activity and potential, integrates with acetylation and other histone marks to organize promoter and enhancer chromatin, and provides a mechanistic handle for researchers investigating gene regulation, developmental transitions, epigenetic dysregulation in disease and related immune pathologies.

References
https://pubmed.ncbi.nlm.nih.gov/41157092/ https://pubmed.ncbi.nlm.nih.gov/20841431/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%